CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025

CERO THERAPEUTICS HOLDINGS, INC.

CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.
CFO Andrew Kucharchuk receives base salary of $300,000/year and a one-time performance bonus of 30% of base salary.
Ehrlich receives equity awards including an option for 238,971 shares (granted March 4, 2025) and a second option for 185,529 shares.
Kucharchuk receives an option for 152,500 shares, subject to board approval, vesting over time and performance milestones.
The new agreements replace prior consulting agreements and convert both roles to full-time employment.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Chris Ehrlich

Chief Executive Officer

CERO · CERO THERAPEUTICS HOLDINGS, INC.

Effective: 2025-06-04
Filed: Jun 02, 2025 23:59 UTC

the Company agreed to employ Mr. Ehrlich as the Company’s Chief Executive Officer as of and from June 4, 2025.

Appointed

Andrew Albert Kucharchuk

Chief Financial Officer

CERO · CERO THERAPEUTICS HOLDINGS, INC.

Effective: 2025-06-04
Filed: Jun 02, 2025 23:59 UTC

the Company agreed to employ Mr. Kucharchuk as the Company’s Chief Financial Officer as of and from June 4, 2025.

Source: SEC EDGAR

accession 0001213900-25-050055

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.